| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TRU Stock Overview
Truscreen Group Limited, together with its subsidiaries, develops, manufactures, and sells cancer detection devices and systems in Mexico, China, Russia, Vietnam, Zimbabwe, and internationally.
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NZ$0.085 |
| 52 Week High | NZ$0.15 |
| 52 Week Low | NZ$0.055 |
| Beta | 0.56 |
| 1 Month Change | 6.25% |
| 3 Month Change | -3.41% |
| 1 Year Change | -42.95% |
| 3 Year Change | -54.05% |
| 5 Year Change | -46.88% |
| Change since IPO | -39.29% |
Recent News & Updates
Here's Why We're Not Too Worried About TruScreen Group's (NZSE:TRU) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
We Think TruScreen Group (NZSE:TRU) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Shareholder Returns
| TRU | NZ Medical Equipment | NZ Market | |
|---|---|---|---|
| 7D | -3.4% | -5.3% | -3.1% |
| 1Y | -43.0% | -14.3% | -11.4% |
Return vs Industry: TRU underperformed the NZ Medical Equipment industry which returned -14.3% over the past year.
Return vs Market: TRU underperformed the NZ Market which returned -11.4% over the past year.
Price Volatility
| TRU volatility | |
|---|---|
| TRU Average Weekly Movement | 5.8% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in NZ Market | 6.5% |
| 10% least volatile stocks in NZ Market | 2.4% |
Stable Share Price: TRU is more volatile than 75% of NZ stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: TRU's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of NZ stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Juliet Hull | https://truscreen.com |
Truscreen Group Limited, together with its subsidiaries, develops, manufactures, and sells cancer detection devices and systems in Mexico, China, Russia, Vietnam, Zimbabwe, and internationally. The company offers the TruScreen cervical cancer screening system, a medical device for detecting the presence of precancerous and cancerous tissue on the cervix in real time. The company was formerly known as TruScreen Limited and changed its name to Truscreen Group Limited in August 2020.
TruScreen Group Fundamentals Summary
| TRU fundamental statistics | |
|---|---|
| Market Cap | NZ$30.84m |
| Earnings (TTM) | -NZ$3.24m |
| Revenue (TTM) | NZ$2.24m |
13.8x
P/S Ratio-9.5x
P/E RatioIs TRU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRU income statement (TTM) | |
|---|---|
| Revenue | NZ$2.24m |
| Cost of Revenue | NZ$900.71k |
| Gross Profit | NZ$1.34m |
| Expenses | NZ$4.58m |
| Earnings | -NZ$3.24m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0089 |
| Gross Margin | 59.76% |
| Net Profit Margin | -144.70% |
| Debt/Equity Ratio | 0.0% |
How did TRU perform over the long term?
See historical performance and comparisonValuation
Is TruScreen Group undervalued compared to its fair value and its price relative to the market?
3.2x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TRU's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TRU's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TRU is unprofitable, so we can't compare its PE Ratio to the Oceanic Medical Equipment industry average.
PE vs Market: TRU is unprofitable, so we can't compare its PE Ratio to the NZ market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TRU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TRU is good value based on its PB Ratio (3.2x) compared to the XO Medical Equipment industry average (4.2x).
Future Growth
How is TruScreen Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
10.2%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TruScreen Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has TruScreen Group performed over the past 5 years?
-5.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TRU is currently unprofitable.
Growing Profit Margin: TRU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TRU is unprofitable, and losses have increased over the past 5 years at a rate of 5.4% per year.
Accelerating Growth: Unable to compare TRU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TRU is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (57.5%).
Return on Equity
High ROE: TRU has a negative Return on Equity (-33.54%), as it is currently unprofitable.
Financial Health
How is TruScreen Group's financial position?
Financial Position Analysis
Short Term Liabilities: TRU's short term assets (NZ$5.5M) exceed its short term liabilities (NZ$649.0K).
Long Term Liabilities: TRU's short term assets (NZ$5.5M) exceed its long term liabilities (NZ$36.2K).
Debt to Equity History and Analysis
Debt Level: TRU is debt free.
Reducing Debt: TRU had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TRU has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TRU has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 4.8% each year.
Dividend
What is TruScreen Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TRU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TRU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TRU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TRU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TRU's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.6yrs
Average management tenure
CEO
Juliet Hull
0.83
Tenure
NZ$36,904
Compensation
Ms. Juliet Hull B. Nurse ATI, MBA MGS, serves as Interim Chief Executive Officer at TruScreen Group Limited since March 2021 and serves as its Executive Director since September 10, 2020 and served as its...
CEO Compensation Analysis
Compensation vs Market: Juliet's total compensation ($USD24.83K) is below average for companies of similar size in the NZ market ($USD370.35K).
Compensation vs Earnings: Insufficient data to compare Juliet's compensation with company performance.
Leadership Team
Experienced Management: TRU's management team is considered experienced (2.6 years average tenure).
Board Members
Experienced Board: TRU's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
TruScreen Group Limited's employee growth, exchange listings and data sources
Key Information
- Name: TruScreen Group Limited
- Ticker: TRU
- Exchange: NZSE
- Founded: 2013
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: NZ$30.844m
- Shares outstanding: 362.87m
- Website: https://truscreen.com
Location
- TruScreen Group Limited
- Equitable House
- Level 6
- Auckland
- 1010
- New Zealand
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/22 06:01 |
| End of Day Share Price | 2022/01/21 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2021/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.